13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      RIPK3 activates parallel pathways of MLKL-driven necroptosis and FADD-mediated apoptosis to protect against influenza A virus

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          Influenza A virus (IAV) is a lytic virus in primary cultures of many cell types and in vivo. We report that the kinase RIPK3 is essential for IAV-induced lysis of mammalian fibroblasts and lung epithelial cells. Replicating IAV drives assembly of a RIPK3-containing complex that includes the kinase RIPK1, the pseudokinase MLKL, and the adaptor protein FADD, and forms independently of signaling by RNA-sensing innate immune receptors (RLRs, TLRs, PKR), or the cytokines type I interferons and TNF-α. Downstream of RIPK3, IAV activates parallel pathways of MLKL-driven necroptosis and FADD-mediated apoptosis, with the former reliant on RIPK3 kinase activity and neither on RIPK1 activity. Mice deficient in RIPK3 or doubly-deficient in MLKL and FADD, but not MLKL alone, are more susceptible to IAV than their wild-type counterparts, revealing an important role for RIPK3-mediated apoptosis in antiviral immunity. Collectively, these results outline RIPK3-activated cytolytic mechanisms essential for controlling respiratory IAV infection.

          Related collections

          Author and article information

          Journal
          101302316
          33345
          Cell Host Microbe
          Cell Host Microbe
          Cell host & microbe
          1931-3128
          1934-6069
          7 September 2016
          16 June 2016
          13 July 2016
          13 July 2017
          : 20
          : 1
          : 13-24
          Affiliations
          [1 ]Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, 19111 USA
          [2 ]Department of Immunology, St. Jude Children’s Research Hospital, Memphis, TN, 38105 USA
          [3 ]Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, PA, 19426 USA
          [4 ]Department of Neurology, Icahn School of Medicine at Mt. Sinai, New York, NY, 10029 USA
          [5 ]Emory Vaccine Center, Emory University, Atlanta, GA, 30322 USA
          [6 ]School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, 19104 USA
          [7 ]Department of Microbiology and Immunology, University of Washington, Seattle, WA, 98109 USA
          Author notes
          [*]

          Equal contribution.

          [#]

          Co-senior authors: S.B., Room 224 Reimann Building, 333 Cottman Ave., Philadelphia, PA 19111, Phone: 215-214-1527. Fax: 215-728-3574. siddharth.balachandran@ 123456fccc.edu

          D.R.G., 262 Danny Thomas Place, Memphis, TN 38105, Phone: 901-595-3488. Fax: 901-595-5766. douglas.green@ 123456stjude.org

          Article
          PMC5026823 PMC5026823 5026823 nihpa814963
          10.1016/j.chom.2016.05.011
          5026823
          27321907
          e0fc75cb-d9f4-428a-8e51-d42cf11e4fb1
          History
          Categories
          Article

          Comments

          Comment on this article